US 11,999,793 B2
Therapeutic anti-CD9 antibody
Hergen Spits, Amsterdam Zuidoost (NL); Paula Maria Wilhelmina Van Helden, Amsterdam Zuidoost (NL); Remko Schotte, Amsterdam Zuidoost (NL); Wouter Pos, Amsterdam Zuidoost (NL); Christien Fatmawati, Amsterdam Zuidoost (NL); Danïel Michiel Go, Amsterdam Zuidoost (NL); Koen Wagner, Amsterdam Zuidoost (NL); and Julien Christian Villaudy, Amsterdam Zuidoost (NL)
Assigned to Kling Biotherapeutics B.V., Amsterdam (NL)
Filed by Kling Biotherapeutics B.V., Amsterdam (NL)
Filed on Sep. 16, 2021, as Appl. No. 17/476,650.
Application 17/476,650 is a division of application No. 16/068,742, granted, now 11,136,407, previously published as PCT/NL2017/050003, filed on Jan. 6, 2017.
Claims priority of application No. 16150698 (EP), filed on Jan. 8, 2016.
Prior Publication US 2022/0064323 A1, Mar. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2896 (2013.01) [A61P 35/00 (2018.01); C07K 14/70596 (2013.01); C07K 16/2818 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/34 (2013.01); C07K 2317/54 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); G01N 2333/70596 (2013.01)] 16 Claims
 
1. A method for at least in part treating a disorder associated with CD9-expressing cells, comprising administering to an individual in need thereof a therapeutically effective amount of an antibody or functional part or functional equivalent that comprises:
a heavy chain CDR1 sequence that has at least 80% sequence identity with the sequence DYAMH (SEQ ID NO:2), and
a heavy chain CDR2 sequence that has the sequence GISWNSGSIVYADSVKG (SEQ ID NO:4), and
a heavy chain CDR3 sequence that has at least 80% sequence identity with the sequence AVSGYYPYFDY (SEQ ID NO:6), and
a light chain CDR1 sequence that has the sequence KSSQSVLYSSNNKNYLG (SEQ ID NO:8), and
a light chain CDR2 sequence that has at least 80% sequence identity with the sequence WASTRES (SEQ ID NO:10), and
a light chain CDR3 sequence that has the sequence QQYYTTP (SEQ ID NO:12);
or administering to said individual a nucleic acid molecule or functional equivalent encoding said antibody or functional part or functional equivalent, or a vector comprising said nucleic acid molecule or functional equivalent, or an isolated or recombinant cell comprising said nucleic acid molecule or functional equivalent, or a composition comprising said antibody or functional part or functional equivalent, or a composition comprising said nucleic acid molecule or functional equivalent, or a composition comprising said vector or said cell.